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Background: Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multi-center longitudinal,
observational study to identify novel phenotypes and biomarkers of chronic obstructive pulmonary disease (COPD). In
a subset of 300 subjects enrolled at six clinical centers, we are performing flow cytometric analyses of leukocytes from
induced sputum, bronchoalveolar lavage (BAL) and peripheral blood. To minimize several sources of variability, we use
a “just-in-time” design that permits immediate staining without pre-fixation of samples, followed by centralized analysis
on a single instrument.
Methods: The Immunophenotyping Core prepares 12-color antibody panels, which are shipped to the six Clinical
Centers shortly before study visits. Sputum induction occurs at least two weeks before a bronchoscopy visit, at which
time peripheral blood and bronchoalveolar lavage are collected. Immunostaining is performed at each clinical site on
the day that the samples are collected. Samples are fixed and express shipped to the Immunophenotyping Core for
data acquisition on a single modified LSR II flow cytometer. Results are analyzed using FACS Diva and FloJo software
and cross-checked by Core scientists who are blinded to subject data.
Results: Thus far, a total of 152 sputum samples and 117 samples of blood and BAL have been returned to the
Immunophenotyping Core. Initial quality checks indicate useable data from 126 sputum samples (83%), 106 blood
samples (91%) and 91 BAL samples (78%). In all three sample types, we are able to identify and characterize the
activation state or subset of multiple leukocyte cell populations (including CD4+ and CD8+ T cells, B cells, monocytes,
macrophages, neutrophils and eosinophils), thereby demonstrating the validity of the antibody panel.
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Conclusions: Our study design, which relies on bi-directional communication between clinical centers and the Core
according to a pre-specified protocol, appears to reduce several sources of variability often seen in flow cytometric
studies involving multiple clinical sites. Because leukocytes contribute to lung pathology in COPD, these analyses will
help achieve SPIROMICS aims of identifying subgroups of patients with specific COPD phenotypes. Future analyses will
correlate cell-surface markers on a given cell type with smoking history, spirometry, airway measurements, and other
parameters.
Trial registration: This study was registered with ClinicalTrials.gov as NCT01969344.
Keywords: Human, COPD, Flow cytometry, Sputum, Bronchoalveolar lavage, ImmunophenotypingBackground
Chronic obstructive pulmonary disease (COPD) is a
chronic disease that is defined by the presence of airflow
limitation that is not fully reversible. COPD is the third-
leading cause of death in the United States [1] and is
projected to become the fifth-leading cause of disease
burden worldwide by the year 2020 [2]. COPD is associ-
ated with a persistent inflammatory immune response in
the lungs in response to inhaled oxidants, including in-
door air pollution from biomass fuels and cigarette
smoke [3]. However, COPD is a complex disease involv-
ing more than just airflow obstruction. In many patients,
COPD is associated with systemic manifestations or co-
morbidities that can result in reduced quality of life and
increased mortality [4]. There is significant heterogeneity
between COPD patients with regard to symptoms, clin-
ical characteristics and co-morbidities, physiology, im-
aging, response to therapy, decline in lung function and
survival [5]. Identifying subtypes of patients may lead to
more targeted and personalized therapeutic treatment.
The Subpopulations and Intermediate Outcomes in
COPD Study (SPIROMICS) is an ongoing multicenter
observational study funded by the National Heart, Lung
and Blood Institute, NIH, with a primary goal of identi-
fying homogenous subgroups of patients with COPD [6].
SPIROMICS is currently assembling a prospective co-
hort of 3200 participants for the collection and analysis
of extensive phenotypic, biomarker, genetic, genomic
and clinical data. In a subset of 300 subjects, peripheral
blood, sputum and bronchoalveolar lavage (BAL) is be-
ing collected to immunophenotype multiple cell popula-
tions using flow cytometry. Cell populations of interest,
including neutrophils, monocytes, macrophages, eosino-
phils, dendritic cells, T cells and B cells, as well as their
activation states, are being identified using a 12-color
antibody panel.
Immunofluorescence analysis by flow cytometry is the
gold-standard for defining leukocyte populations. How-
ever, due to the complexity and sensitivity of flow cy-
tometry, there are significant methodological hurdles
when applied to a multicenter trial. Early studies from
the Multicenter AIDS Cohort Study (MACS), in whichfour flow cytometry laboratories analyzed identical per-
ipheral blood specimens, identified the importance of
standardizing the model of flow cytometer, the antibody
reagents and fluorochromes, the procedure for sample
preparation and the procedure for sample analysis [7].
Many multicenter trials continue to stain the sample lo-
cally and use the flow cytometry instruments that are
available at each participating institution [8-10]. Other
studies have employed fixatives to stabilize receptor ex-
pression before staining, particularly in peripheral blood
samples, with subsequent centralized core staining and
flow cytometric analysis has also been explored; however
preservation of individual surface markers by this ap-
proach was variable [11,12].
The goal of this sub-study is to provide state-of-the-
art immunophenotyping of sputum, blood and BAL to
be correlated with the abundance of other clinical, radio-
graphic, physiological, genetic and biomarker data being
collected on this cohort. We took the approach of “just-in-
time” provision of reagents from a centralized Immunophe-
notyping Core, which prepares the 12-color antibody panels
and ships them to the institutions as needed. On the day
when samples are collected at each clinical site, they are
stained without pre-fixation, then fixed and shipped over-
night express on cold packs to the Immunophenotyping
Core for data acquisition and analysis on a single flow cyt-
ometer. The choice of leukocyte cell types and their recep-
tors was based on a series of pre-specified hypotheses plus
research interests of the coauthors. This interim report
demonstrates the feasibility of our approach, which may
be of value in the design of multicenter trials in COPD or
other disease states.
Materials and methods
Ethics statement
All clinical investigations are conducted according to the
principles of the Declaration of Helsinki. The study
protocol was approved by the individual institutional
review boards (Columbia University; Weill Cornell Medical
College; University of California Los Angeles; University of
California San Francisco; University of Michigan, University
of Utah; Wake Forest University). All participants
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ten informed consent before they undergo any research
activities or procedures.
Study design and logistics
A subgroup of 50 subjects from each of six clinical sites
(total n = 300) is being enrolled from the parent SPIRO-
MICS study. The enrollment strata for the bronchoscopy
sub-study are described in Table 1. Subjects participate
in this sub-study during two separate visits. At the first
visit, a sputum sample is collected by induction. In the
second visit, which takes place two to four weeks later,
peripheral blood and bronchoalveolar lavage samples are
collected.
The SPIROMICS clinical sites are broadly distributed
geographically, being located in Ann Arbor (University
of Michigan); Los Angeles (University of California); New
York City (Columbia & Cornell Universities); Salt Lake
City (University of Utah); San Francisco (University of
California); and Winston-Salem (Wake Forest University).
To assure efficient communication, we follow a stan-
dardized notification process. Study coordinators at the
Clinical Centers are required to notify both the Immu-
nophenotyping Core and their local collaborating la-
boratory as soon as the first bronchoscopy sub-study
visit is scheduled, so that antibody panels can be pre-
pared and shipped overnight to that site. Notification
occurs by email to multiple individuals at both the clinical
sites and the Immunophenotyping Core, to minimize the
chance that an absence of one individual will interfere
with the tight shipping schedule. The individuals primarily
responsible for this protocol at both the Clinical Centers
and the Immunophenotyping Core follow a strict pol-
icy of immediately “replying to all” at both sites, con-
firming receipt of each email and repeating back the
received information, to affirm that the message has
been received correctly.
Next, assay tubes, each containing all the antibodies
(or isotype controls) for a given cell type or groups of re-
lated cell types, are prepared by the Immunophenotyp-
ing Core. Each tube is identified using labels supplied by
the SPIROMICS Genomics and Informatics Core (GIC)
at the University of North Carolina. These labels are spe-
cific to sample type and subject, but do not include the
SPIROMICS-wide subject identifier. Thus, the Immuno-
phenotyping Core is blinded to any clinical informationTable 1 Planned subject enrollment distribution by strata
Never-smokers Smokers without
airflow obstruction
Smoking status <1 pack year >20 pack years
Lung function FEV1/FVC >0.7 FEV1/FVC >0.7
Sample size N = 60 (20%) N = 60 (20%)about the subjects at the time of the flow cytometry ana-
lysis, as the only link between sample labels and subject
IDs is held by the GIC.
Once antibodies are aliquoted, tubes are capped and
centrifuged at 300 × g for 5 minutes, the tubes are placed
in wire tacks, which are wrapped in aluminum foil to
shield them from light, and are stored at 4°C until ship-
ment. Tubes are affixed with a sample-specific label
(which can later be matched by the GIC to specific subject
information) and then are shipped from the Immunophe-
notyping Core to the Clinical Centers between 3–7 days
before the scheduled appointment. The Immunopheno-
typing Core notifies the Clinical Center by email that the
assay tubes have been shipped and provides the tracking
information. When assays are shipped, the Immunophe-
notyping Core records the assay ID number from the la-
bels, plus the date and Clinical Center to which that
particular assay was shipped. This information is trans-
mitted to the GIC.
An identical process of email communication between
the Clinical Centers, the Immunophenotyping Core and
the GIC is followed once the sample has been collected,
stained and fixed. Thus, the GIC records the date on
which an assay was shipped; the Immunophenotyping
Core records the date on which it was received, facilitating
prompt location of any assays that become delayed or
lost in transit. To reduce the chance that assays will not
be properly chilled during transit, shipping in either dir-
ection is permitted only Monday through Thursdays.
Additionally, care is taken to assure that the timing of
holidays (especially Federal, given that the Immunophe-
notyping Core is a VA facility) is considered before ship-
ments are released.
Biospecimen collection
Sputum induction was performed according to the
methods of Alexis et al. [13]. Personnel at the clinical
sites involved in sputum induction and sample process-
ing received onsite, in-person training from Dr. Alexis.
Briefly, subjects undergo seven-minute exposures to in-
creasing concentrations of aerosolized hypertonic saline
by inhaling via a mouthpiece. To minimize oral contam-
ination of induced sputum specimens, subjects are asked
to rinse their mouths with water, to blow their noses
and to clear their throat at the end of each inhalation
period, then to “cough from their chest” and immediatelySmokers with mild to
moderate COPD
Smokers with severe COPD
>20 pack years >20 pack years
FEV1 > 50% predicted 50% > FEV1 > 30% predicted
N = 140 (47%) N = 40 (13%)
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their mouths. To assure subject safety, spirometry is per-
formed during the inhalation period and again at the end
of each seven minute exposure. The saline concentrations
used and frequency of spirometric testing vary according
to the subject’s baseline forced expiratory volume in 1 sec-
ond (FEV1). Subjects with baseline FEV1 ≥ 50% predicted
inhale 3%, 4% and 5% saline, and undergo spirometry two
minutes into each exposure and at the end of the expos-
ure. By contrast, subjects with baseline FEV1 < 50% pre-
dicted inhale 0.9% and 3% saline, and undergo spirometry
at 1, 2, 5 and 7 minutes of exposure. If at any point the
FEV1 decreases by >20% from baseline, the induction is
stopped; otherwise, subjects either continue the current
exposure period or proceed to the next saline concentra-
tion. Sputum samples were kept on ice throughout the in-
duction procedure and processed for immunophenotyping
immediately following collection.
At the second visit, during which blood and BAL are
collected, post-bronchodilator FEV1 is measured before
any procedures. Only subjects with an FEV1 > 30% pre-
dicted that day are allowed to participate in the bron-
choscopy visit. At the time of IV placement, blood is
drawn into a 10 ml heparin plasma tube, and immedi-
ately to the laboratory for immunophenotyping staining.
A complete blood count (CBC) is also collected, and
processed by the medical center clinical laboratory.
The BAL sample for Immunophenotyping is only one
portion of collection of multiple samples that comprise
the entire Bronchoscopy sub-study. BAL is performed in
the right middle lobe and lingula by instilling two aliquots
of 40 mL and one aliquot of 50 mL of sterile saline per
lobe (i.e., 130 mL per lobe, total volume = 260 mL per
subject), which is withdrawn by gentle manual suction.
The BAL return is collected into specifically designated
specimen traps, kept on ice. The BAL from both lung
sites was pooled and used for immunophenotyping.
Antibody panels
We designed 12-color monoclonal antibody panels with
isotype controls to analyze multiple leukocyte popula-
tions. The antibody panel, with clones listed in paren-
theses, is shown in Table 2. The panels for BAL and
sputum differ from the panel for peripheral blood in that
they do not contain antibodies for basophils or endothelial
cells. Additionally, the sputum panel does not contain
antibodies for dendritic cells or B cells. These choices
were made based on pilot data from our laboratory indi-
cating that these cell types were present in such low fre-
quency as to be impractical to identify. Antibodies and
isotype-matched controls were directly conjugated to
either fluorescein isothiocyanate (FITC), eFluor 450,
phycoerythrin (PE), phycoerythrin-cyanine 5 (PE-Cy5),
peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5),phycoerythrin Texas red (PE-TR), phycoerythrin-cyanine
7 (PE-Cy7), allophycocyanin (APC), allophycocyanin-
cyanine 7 (APC-Cy7), BD Horizon™ V500 (V500), Pacific
Blue, Alexa Fluor 700 (AF 700), and QDot® 655. Vendors
from which antibodies were purchased include Biolegend
(San Diego, CA), eBioscience (San Diego, CA), BD
Biosciences (San Jose, CA), R&D Systems (Minneapolis,
MN), Miltenyi Biotec (Auburn CA), and Invitrogen
(Carlsbad, CA). Antibodies against CX3CR1, CD133,
and their respective isotypes, were purchased unconju-
gated, and we used Lightning-Link antibody labeling kit
(Novus Biologicals, Littleton, CO) to conjugate these anti-
bodies to APC-Cy7 and Atto 700, respectively.
Antibodies are centrally prepared for each clinical site
at the Immunophenotyping Core at the VA Ann Arbor
Healthcare System. Antibodies are aliquoted into flow
tubes (BD #352008 and #35203; Becton Dickinson)
which are capped, placed in a rack (Fisher #14-793-14),
and covered with aluminum foil. Antibodies are shipped
overnight in a Styrofoam box with multiple cold packs,
frozen to −20°C, and typically arrive at the clinical site
1–3 days before the study visit.
Staining of samples
At each clinical site, mucus plugs from the sputum sam-
ple are selected, weighed, and then incubated with 1×
Sputolysin® Reagent (EMD Millipore, Billerica, MA) in a
37°C water bath for 20 minutes. Samples are washed and
filtered before resuspending the cell pellet in Staining
Buffer with FBS (BD #340345; BD Biosciences). The spu-
tum assay antibody tubes from the Immunophenotyping
Core are briefly centrifuged and then the entire sputum
sample is divided among seven antibody tubes (100 μL
per tube). Tubes are covered with aluminum foil and
incubated at room temperature for 25 minutes with con-
tinuous shaking or rocking (depending on the equip-
ment available at the clinical site laboratory). After the
incubation, samples are washed with 2 mL Staining
Buffer, centrifuged, and resuspended for storage in 2%
freshly-prepared formaldehyde in PBS. Tubes are then
stored at 4°C in a rack wrapped in aluminum foil before
being shipped back to the Immunophenotyping Core.
BAL samples are centrifuged and resuspended in Staining
Buffer, then 100 μL of the BAL sample is added to each
of the BAL assay antibody tubes. Staining then proceeds
as described above for sputum samples.
Blood tubes are inverted eight times and then 100 μL
of the undiluted blood sample is added to each of the
blood assay antibody tubes. Similar to the staining pro-
cedure for sputum and BAL, samples are incubated with
the antibodies for 25 minutes. Next, to remove red blood
cells, 2 mL of 1× BD Pharm Lyse (BD Biosciences) are
added to each tube and incubated at room temperature
for another 25 minutes. Samples are centrifuged and
Table 2 Standardized antibody panel
Leukocyte population
Fluorochrome (directly conjugated to monoclonal antibody)
FITC PE PE-Cy5 PerCP-Cy5.5 PE-TR PE-Cy7 APC APC-Cy7 V500 Pacific blue AF 700 QDot 655
Surface antigen detected with monoclonal antibody clone used (italicized)
Dendritic cells# BDCA-2
AC144
BDCA-1
AD5-8E7
CD123 6H6 CCR2 TG5 CD45 HI30 CD103 B-Ly7 BDCA-3 AD5-
14H12
CX3CR1 2A9-1 HLA-DR
L243
CD11c 3.9 CD11b CBRM1/5 CD3 7D6 &
CD19 SJ25-C1
Mø &
monocytes
CD14 HCD14 CCR6 R6H1 CD16 3G8 CCR2 TG5 CD45 HI30 TLR2 T2.5 CD206 15-2 CX3CR1 2A9-1 HLA-DR
L243
CD11c 3.9 CD11b CBRM1/5
Mø &
monocytes
CD14 HCD14 Axl 108737 CD16 3G8 DC-Sign
9E9A8
CD45 HI30 TLR4 HTA125 Mertk 125518 HLA-DR
L243
CD11c 3.9 CD11b CBRM1/5
Basophils*# CD33 HIM3-4 CD9C3-3A2 CD13 TuK1 CD203c
NP4D6
CD45 HI30 CD63 H5C6 CD22 HIB22 CD34 581 HLA-DR
L243
CD69 FN50 CD11b CBRM1/5 CD19 SJ25-C1
Eosinophils CD49d 9 F10 CDw125 A14 CD16 3G8 CD69 FN50 CD45 HI30 CCR3 5E8 CD34 581 CD11b CBRM1/5
Neutrophils CD177
MEM-166
CD16b
CLB-gran 11.5
CXCR1 8 F1 CD66b G10F5 CD45 HI30 TLR4 HTA125 CXCR2 5E8 CD10 HI10a TLR2 T2.5 CD11b CBRM1/5
Endothelial
cells*#
CD33 HIM3-4 CD146
SHM-57
VCAM-1
STA
VEGFR2
HKDR-1
CD45 HI30 PECAM
WM59
CD144 16B1 CD34 581 ICAM-1
HCD54
CD133 293C3 CD37D6 &
CD19 SJ25-C1
B cells# IgD IA6-2 CD80 2D10.4 CD86 B7-2 CD27 O323 CD45 HI30 CXCR4 12G5 CD23 EBVCS-5 CD20 2H7 CD38 HIT2 CD19 SJ25-C1
T cells γδ -TCR B1.1 CTLA-4 14D3 CD28
CD28.2
CD27 O323 CD45 HI30 ICOS ISA-3 CD56 CMSSB CD62L
DREG-56
CD3 UCHT1 CD8 OKT-8 CD4 OKT-4
T cells CCR7 150503 CCR5 T21/8 CXCR3 1C6 CD27 O323 CD45 HI30 CD56 CMSSB CD62L
DREG-56
CD3 UCHT1 CD8 OKT-8 CD4 OKT-4
*not included in BAL samples; #not included in sputum samples.
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formaldehyde in a refrigerator wrapped in aluminum foil.
Flow cytometry instrument setup and data acquisition
Samples are wrapped in aluminum foil and are shipped
overnight in a Styrofoam box with cold packs to the
Immunophenotyping Core. Upon arrival, samples are
physically inspected and any issues (e.g. cracked tubes,
inconsistent volumes, missing tubes) are recorded along
with the sample ID. Samples are transferred to a 96-well
U-bottom plate and data are acquired on an LSR II flow
cytometer (BD Bioscience, San Jose, CA) with a High
Throughput Sampler, equipped with the following four
lasers, listed with their associated fluorochromes and fil-
ter sets: 488 nm blue laser (APC-Cy7: 735 nm long-pass
(LP), 780/60 nm short band-pass (SBP); AF700: 690 nm
LP, 730/45 nm SBP; APC: 660/20 nm SBP); 405 nm vio-
let laser (Qdot655: 630 nm LP, 660/20 nm SBP; Horizon
V500: 505 LP, 530/30 SBP; Pacific Blue: 450/50 SBP);
633 nm red HeNe laser (PerCP-Cy5.5: 685 nm LP, 695/
40 SBP; FITC: 505 LP, 530/30 SBP); and a 561 nm
yellow-green laser (PE-Cy7: 735 nm LP, 780/60 nm SBP;
PE-Cy5: 635 nm LP, 670/30 nm SBP; PE-TR: 600 nm LP,
610/20 nm SBP; PE: 582/15 nm SBP).
Data are collected using FACSDiva software (BD
Biosciences) with automatic compensation. CS&T Research
beads (BD Biosciences) are used during instrument setup
to maintain baseline performance values, thereby ensuring
that the cytometer performed the same every time.
Because cell yields varied, we collect all possible events to
maximize our ability to detect rare populations.
Within 1–2 days after the sample has been run on the
flow cytometer, we perform an initial quality check. We
record the absolute number of CD45+ leukocytes in the
sample and also look at the percentage of low side scat-
ter cells, indicative of lymphocytes, and high side scatter
cells, such as macrophages, neutrophils, and monocytes.
Flow cytometry data analysis
Data are analyzed by two trained individuals (SC, VRS)
using FlowJo software v.9.6.2 (Tree Star, Ashland, OR)Table 3 Number and percentage of usable specimens by clini
Site 1 Site 2 Sit
Sputum visits, n: 16 26 38
Usable specimens, n 13 21 34
Usable specimens,% 81% 81% 89
Blood & BAL visits, n: 7 26 28
Usable blood specimens, n 6 22 25
Usable blood specimens, % 86% 85% 89
Usable BAL specimens, n 6 21 22
Usable BAL specimens, % 86% 81% 76on Macintosh Quad-Core Intel Xeon computers running
OS X 10.10.1 (Apple; Cupertino, CA). We use pre-printed
sample report forms and a flow analysis worksheet to
standardize the process. All analyses undergo a secondary
evaluation by a third individual (CMF) to help maintain
consistency in the gating and analysis between samples.
Data, including analysis files, are immediately backed up
to DVD-R disks.
Statistical analysis
Analyses were performed using GraphPad Prism 6.0
(GraphPad Software, Inc., La Jolla, CA) on a Macintosh
Quad-Core Intel Xeon computer running OS 10.10
(Apple; Cupertino, CA). A two-tailed p value of < 0.05
was considered to indicate significance.
Results
Sample acquisition success rate
As of September 17, 2014, a total of 152 sputum samples
and 117 blood/BAL samples had been returned to the
Immunophenotyping Core. Disparity between collection
of sputum samples and of blood plus BAL samples from
what was planned appears to have resulted primarily
from missed or yet to be completed return visits, and
not from any adverse events related to the study proce-
dures. For each specimen, we performed an initial ana-
lysis of the number of CD45+ cells in sputum, blood,
and BAL, stratified by clinical site. Samples averaged
7.7×104 ± 8.2×104 (mean ± SD), 8.9×104 ± 10.7×104, and
20.3×104 ± 36.6x104 CD45+ events (leukocytes) per tube
for sputum, BAL and blood, respectively. Samples con-
taining fewer than 1×104 leukocytes are deemed un-
usable and are not analyzed. Low cell yield was most
typically seen in the sputum and BAL samples. We have
deliberately not yet broken the codes linking samples to
subjects, so that initial analyses are not biased by know-
ledge of clinical data.
Our preliminary analyses indicate that a total of 126 of
152 sputum samples (83%), 106 of 117 blood samples
(91%) and 91 of 117 BAL samples (78%) provided usable
data (Table 3). It seems likely that there may have been acal site
e 3 Site 4 Site 5 Site 6 Total
30 23 19 152
27 17 14 126
% 90% 74% 74% 83%
19 19 18 117
19 17 17 106
% 100% 89% 94% 91%
12 15 15 91
% 63% 79% 83% 78%
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particularly sputum. The percentage of usable sputum
data has increased from 69% in 2012, to 88% in 2013,
and 92% in 2014. BAL samples also showed a modest in-
crease: 71% usable samples in 2012, 78% in 2013 and
80% in 2014 (data not shown).
Processing errors may also account for some of the
unusable data. The most commonly detected processing
error was resuspension of the samples in an incorrect
fixative volume, such that the concentration of parafor-
maldehyde, which must be held constant to stabilize the
light scatter and antibody labeling, was likely much
lower than the 2% specified in the protocol. Other less
common errors result from shipping delays, which re-
sulted in samples no longer protected by the ice packs;
cracked tubes with low or missing sample; and improp-
erly capped tubes, resulting in loss of entire samples. Al-
though there was variation between clinical sites in the
percentage of usable samples of different types, no site
was routinely underperforming compared to the other
sites (Table 3), supporting our impression that random
errors, rather that systematic problems, were responsible
for lost data.
Duration between fixation and data acquisition has only
minor effect on fluorescence intensity
One variable in this study is the duration between fixa-
tive addition and data acquisition on the flow cytometer.
This duration typically varies between two and seven
days, because sites that have study visits on Thursday or
Friday are unable to ship specimens until the following
Monday. To determine whether time of storage in PFA
affected fluorescent intensity, in locally-performed pilot
experiments, we analyzed blood and BAL samples at
days 2, 5, and 7 post-PFA. Results indicated no differ-
ence in forward scatter, side scatter or CD45+ staining
(not shown). Among 68 surface molecules, fluorescence
intensity for 61 was either unaffected by storage in PFA,
as shown for CD16 (Figure 1A), or had modest increases
in specific staining and in the corresponding isotype
control, such that there was no difference in overall
positive staining. In blood specimens, antibodies against
TLR4 (PE-Cy7), gamma-delta T cell receptor (FITC),
and CCR7 (FITC) had increased specific fluorescence
(relative to isotype control) from day 2 to day 5, but no
further increase at day 7 (data not shown). In BAL
specimens, antibodies against BDCA-1 (PE), CX3CR1
(APC-Cy7), and TLR2 (eFluor 450) also showed mod-
est increases in specific fluorescence at days 5 and 7
(Figure 1B). Only CD103 (PE-Cy7) in the BAL samples
exhibited decreased fluorescent intensity, which was
seen at both days 5 and 7 (Figure 2C). Although small
in absolute terms, these changes will need to be accounted
for in future analyses. Importantly, however, staining forthe vast majority of antigens were unaffected by duration
of storage in PFA.
Identification of T cell populations in blood, sputum and BAL
Lung T cells have been linked to progression of COPD,
especially of emphysema, in multiple studies [14-19].
We used a combination of anti-CD45 (leukocyte common
antigen), forward and side light scatter properties, and dif-
ferential expression of lineage-specific surface markers to
identify leukocyte populations, as has been previously
shown to be effective for sputum leukocytes [13,20]. To
identify CD4+ and CD8+ T cells, we first gated on CD45+
CD3+ cells with a low side scatter. Representative staining
demonstrates the ability of this strategy plus comparison
to isotype controls to distinguish CD4+ and CD8+ T cells
in blood, BAL and sputum (Figure 2). The numbers in
each quadrant indicate the percentage of that subset
among all CD45+ cells. These numbers are consistent
with what other studies have found in sputum [21], blood
and BAL [22].
Identification of macrophage populations in sputum and
BAL
Alveolar macrophage (AMø) numbers are increased and
their function is altered in COPD [23]. There is consider-
able interest in whether polarization of their gene prod-
ucts drives inflammation in COPD [24,25]. To identify
AMø, we gated on CD45+, auto-fluorescent cells and then
selected HLA-DR+ CD11c + cells (Figure 3). This ap-
proach was chosen after a preliminary analysis of a var-
iety of alternative gating approaches, including use of
Mertk (a putative pan-Mø marker in mice) [26], as the
one giving the most unambiguous distinction of mature
AMø. Although CD11b is included in the panel for ana-
lysis, we did not use it to gate on macrophages, as AMø
have been shown to be negative for CD11b, unless acti-
vated, therefore their expression is not uniformly positive
[27]. As expected, BAL samples contained the largest
percentage of macrophages. As the numbers of subjects
increase, this dataset will be analyzed further for correl-
ation of macrophage surface receptor expression with
spirometrically-defined disease severity and other clin-
ical data.
Identification of monocyte populations in blood, sputum
and BAL
Monocytes constitute 5 to 10% of peripheral blood leu-
kocytes where they circulate for several days before mi-
grating into tissues. The degree to which recruitment of
blood monocytes contributes to the expansion of the
mononuclear phagocyte population in COPD is con-
tested. Monocytes were originally divided into “classical”
CD14++ CD16- cells and “nonclassical” CD14+ CD16+
cells. The classical monocytes were considered to be
Figure 1 Storage in PFA affects fluorescent intensity of specific surface receptor-monoclonal antibody combinations. After addition of
PFA, BAL samples were divided into three samples and data was acquired after storage at 4°C for either 2, 5, or 7 days. A) CD16 (and the majority
of the surface antigens) showed no change in fluorescent intensity between days 2, 5, and 7. B) TLR2 showed an increase in fluorescent intensity
at day 5 and at day 7. C) CD103 was the only receptor to show a decrease in fluorescent intensity at days 5 and 7.
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stitute the majority of all monocytes in healthy persons,
whereas the nonclassical monocytes more closely resem-
ble resident tissue macrophages [28-30]. A third subset
of peripheral blood monocytes, termed “intermediate”
monocytes are CD14++ CD16+ [31]. It is not clear
whether these intermediate monocytes have a biologic-
ally meaningful role or are an intermediate step in the
differentiation of monocytes but they have been shown
to be increased in certain conditions including rheuma-
toid arthritis and severe asthma [32].
In our study, monocytes were readily identified in all
three compartments using CD14 and CD16 antibodies,after gating on CD45+, non-autofluorescent cells with a
medium side-scatter that were HLA-DR+, relative to iso-
type controls (Figure 4A-4C). We chose to define mono-
cytes by HLA-DR+ staining, rather than expression of
CD11b (typically positive on monocytes in peripheral
blood) or CD11c (negative on blood monocytes, but po-
tentially upregulated in GM-CSF-rich environments such
as the lungs), so that we could independently analyze ex-
pression of the latter two markers in samples other than
blood. As shown in the representative staining (Figure 4D),
we can easily see distinct populations for the classical,
non-classical, and intermediate monocytes in peripheral
blood.
Figure 2 Representative staining of CD4+ and CD8+ T lymphocytes in blood, BAL, and sputum. Samples of peripheral blood (A, D), BAL
(B, E) and sputum (C, F) were gated on cells that were CD45+, CD3+, and had a low side-scatter. Next, using the isotype control (A-C), quadrants
denoting specific staining for CD4 (horizontal axis) and CD8 (vertical axis) were determined (D-F). Numbers in the CD4+ and CD8+ quadrants
represent the percent of each subset among all CD45+ cells.
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alveolar macrophages due to their reduced size and
granularity, evident by forward scatter and side scatter
(data not shown). Monocytes were again divided into
the three populations: classical, intermediate, and non-
classical (Figure 4E, 4F). The populations appear to be
more limited to the classical and intermediate pheno-
types, reminiscent of a gating strategy developed by
Brittan et al. [33] which uses the terms “inducible” and
“resident”, respectively, due to the observation that LPS
inhalation resulted in an increase in the CD14++ CD16-
population, in comparison to a saline-treated group, but
the CD14++ CD16+ population was unchanged between
groups [33]. We also found that the monocytes from
BAL and sputum were predominantly CD14++ CD16+,
the so-called “resident” monocytes (Figures 4E, 4F).Identification of myeloid dendritic cell (mDC) populations
in blood, sputum and BAL
In the present study, we examined markers of three
human pulmonary DC subsets: myeloid DC type 1
(mDC1), myeloid DC type 2 (mDC2), and plasmacytoid
DCs (pDCs). DCs were only analyzed in BAL and blood
due to concerns that they would be too small of a popu-
lation to identify in sputum. To identify the DC subsets,
we used blood dendritic cell antigen (BDCA) markers,
which we and others have previously shown accurately
identifies these cell types in lung parenchyma [34,35].
First, CD45+ cells were selected followed by exclusion of
cells that were positive for either CD3 or CD19+ cells, and
of cells with a high forward scatter or high side-scatter.
Next, mDC1 cells were identified as being double-positive
for HLA-DR and BDCA-1 (CD1c), whereas mDC2 cells
Figure 3 Representative staining of macrophages in BAL and sputum. To identify macrophages in samples of BAL (A, C) and sputum (B, D),
we gated on CD45+ auto-fluorescent cells and used isotype controls (A,B) to gate on cells specifically staining for HLA-DR+ CD11c + (C, D). Numbers
represent the percent of AMø among all CD45+ cells.
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BDCA-3 (CD141). To identify pDC, we selected cells that
were CD123+ and BDCA-2 (CD303) +.
Using this method we were able to identify mDC1
subsets in blood and BAL (Figure 5). Similar results were
found for mDC2 and pDCs (data not shown). CD11c,
CD11b, and CD103, which are also routinely used to
identify DCs, were also included in the panel for DCs.
Future analyses could utilize these markers to perform
more in-depth analysis of DC subsets and to compare al-
ternative methods of DC identification.
Identification of neutrophil populations in blood, sputum
and BAL
The concept that neutrophils contribute centrally to
emphysema stems primarily from genetic deficiency of
alpha-1 antiprotease, which inhibits neutrophil elastase,although it is now recognized that this acute phase react-
ant has important actions independent of elastase inhib-
ition [36]. Hence, clarifying the exact role of neutrophils
in COPD phenotypes is an important goal. We identified
neutrophils by gating on CD45+, high side scatter
cells and then, based on appropriate isotype control
(Figures 6A-6C), selected cells that were positive for
two neutrophil-specific surface markers [37], CD16b
and CD66b (Figure 6D-6 F). From the representative
staining we saw that neutrophils were most abundant in
blood and sputum samples, as expected, and were very
infrequent in BAL.
In peripheral blood samples, we also observed a
CD66b + CD16b- population (R1 in Figure 6D), which
was not present in the BAL or sputum samples. In design-
ing this study, we had hypothesized that in COPD subjects
we might see a population of circulating neutrophils
Figure 4 CD14 and CD16 identify populations of monocytes in blood, BAL, and sputum. To identify monocyte in samples of peripheral
blood (A, D), BAL (B, E) and sputum (C, F), we first gated on non-autofluorescent, CD45+ cells with a medium side-scatter, then using isotype
controls (A-C), chose HLA-DR+ cells (D-E). In all analyses, we then separated the monocytes into “classical” CD14++ CD16- cells (R1), “intermediate”
CD14++ CD16+ (R2), and “nonclassical” CD14+ CD16+ (R3) cells. Numbers represent the percent of each monocyte subset among all CD45+ cells.
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CD16b- (low) and CD10- cells [38]. We gated on both
CD16b low and high populations and analyzed expres-
sion of CD10 (Figure 6B). The CD66b + CD16b- cells
had reduced expression of CD10, especially in com-
parison to the CD66b + CD16b + cells, suggesting that
we are able to identify a population of circulating im-
mature neutrophils.
Identification of eosinophil populations in blood, sputum
and BAL
Eosinophilic lung inflammation appears to identify a sub-
set of COPD patients who are more responsive to cortico-
steroids or leukotriene inhibition [39-41]. We identified
eosinophils in blood and BAL by first gating on CD45+
high side scatter cells and then identifying cells that,
compared to isotype controls (Figure 7A-7C) were
CCR3+ and CD16- [42] (Figure 7D-7F). In sputum
samples, we also identified a cell population that was
CCR3+ but based on the isotype control, they appearedto be positive for CD16. Eosinophils do contain intra-
cellular CD16 and it has been shown that blood eosino-
phils express surface CD16 when stimulated in vitro with
platelet-activating factor or IFN-γ [43]. Hence, these pre-
liminary data are compatible with activation of eosinophils
in the airways of some subjects with COPD. In future
studies once we have data on all subjects, we will look for
correlations between eosinophil CD16 expression and
clinical characteristics.
Discussion
This interim analysis, describing the design and early
data collection of a clinical trial involving six clinical
centers throughout the United States, demonstrates
the feasibility of our approach of “just-in-time” provision
of antibodies, distributed staining and fixation, and cen-
tralized analysis to perform 12-color immunophenotyping
of samples from three different tissue origins. We have
demonstrated successful identification of multiple leukocyte
cell populations, including CD4+ and CD8+ T cells,
Figure 5 BDCA-1 and HLA-DR identify mDC1 cells in blood and BAL. To identify dendritic cells in samples of peripheral blood (A, C) and
BAL (B, D), we first gated on CD45+ cells, then excluded CD3+, CD19+, and cells with a high forward and side-scatter, and finally using isotype
controls (A,B), chose HLA-DR and BDCA-1 double-positive cells (C,D). Numbers represent the percent of mDC1 cells among all CD45+ cells.
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in blood, BAL and sputum, thereby demonstrating the
validity of our antibody panel and the fixation method.
We have also shown that the vast majority of samples
provide usable data, supporting the feasibility of this
logistic approach. This design should be considered for
immunophenotyping in comparable clinical studies in
other disease states.
Our approach differs from that of several other multicen-
ter trials. The Multicenter AIDS Cohort Study (MACS)
used four flow cytometry laboratories to analyze identical
peripheral blood specimens. MACS identified the import-
ance of standardizing the following variables: (1) the
model of flow cytometer; (2) the antibody reagents and
fluorochromes; (3) the procedure for sample preparation;
and (4) the procedure for sample analysis [7]. Our approachallows us to standardize three out of those four variables.
In our study, all samples are run on the same instrument,
a modified LSR II flow cytometer containing a high-
throughput sampler to improve efficiency of analysis and
a yellow-green laser that permits use of multiple PE-
conjugated fluorochromes. Data are collected and ana-
lyzed by a small team of highly trained scientists with
adherence to a standardized gating strategy and fre-
quent evaluation of the raw data and instrument con-
trols. We have even minimized variability in the
antibody reagents and fluorochromes by preparing the
antibodies at the centralized core before shipping them
to the Clinical Centers. In comparison, other multicen-
ter trials have opted to combine local sample staining
with the flow cytometry instruments that are available
at each participating institution, although often the
Figure 6 Representative staining of neutrophils in blood, BAL, and sputum. To identify neutrophils in samples of peripheral blood (A, D),
BAL (B, E) and sputum (C, F), we gated on CD45+, high side-scatter cells that were positive for both CD16b (horizontal axis) and CD66b (vertical
axis), relative to isotype controls (A-C). Numbers in the quadrants (D-F) represent the percent of the major neutrophil population among all
CD45+ cells. In the blood analysis (panel D), a CD16b- (low) CD66b + population was also identified (R1). G) Histograms depicting expression of
CD10 in the R1 (blue line) and R2 (green line) populations, relative to isotype control (red line).
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lasers [8-10]. Della Porta et al. attempted to control for
this variability by including daily instrument quality
controls, including fluorescence standardization, to en-
sure consistent operation. However, the analysis was
not centrally reviewed and was performed using multiple
platforms [10]. In the study by Benevolo et al., laboratories
had either a 3- or 4-color instruments, which resulted in
the use of different antibody panels between centers. Tominimize that variable, all data in that study were
reviewed by a single person [9].
Although in our study there is a single procedure for
sample preparation, given that six different sites are re-
sponsible for staining the samples, there is likely some
variability being introduced at this stage. We considered
the idea of cryopreserving or stabilizing samples and
then shipping them to a centralized flow cytometry core
for staining and analysis, but ultimately decided against
Figure 7 Eosinophils in blood, BAL, and sputum express CCR3 but have variable expression of CD16. To identify eosinophils in samples
of peripheral blood (A, D), BAL (B, E) and sputum (C, F), we gated on cells that were CD45+ with a high side scatter that were also CCR3+
(vertical axis), relative to isotype controls (A-C). In blood (panel D) and BAL samples (panel E), eosinophils were also CD16- (horizontal axis). In
sputum samples (panel F), eosinophils were positive for CD16. Numbers represent the percent of each subset among all CD45+ cells.
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antigens is quite variable [11,12] (and our own unpub-
lished data from pilot experiments). For the most part,
our preliminary analyses have not demonstrated system-
atic differences between clinical centers for staining
efficiency.
Another variable that we are unable to control entirely
using this approach is the amount of time that the sam-
ples remain in PFA before data collection on the flow
cytometer. Although we stipulate that sites send samples
back as soon as possible, samples that are collected on a
Thursday or Friday are not shipped until the next Monday.
Excluding those days from sample collection was not
compatible with the overall logistics of the Bronchoscopy
sub-study. An essential feature of our study design was
sample fixation using 2% paraformaldehyde post-staining
to permit delayed analysis. However, paraformaldehyde it-
self affects flow cytometry readings. Staining with PFA hasbeen shown to result in a slight decrease in fluorescent in-
tensity [44] and a decrease in forward scatter and side
scatter [45]. Our analysis of changes in fluorescence inten-
sity for 68 leukocyte surface receptors for up to seven days
generally agrees with a previous analysis showing that
staining generally remained consistent and highly repro-
ducible at days 1, 3 and 5 post-staining [44]. However, we
found better preservation of staining intensity at day 7
than in that previous study, although two of the four re-
ceptors they studied were also stable at 7 days, suggesting
that these changes are receptor-specific. Furthermore, we
did not observe a change in forward scatter and side scat-
ter. Of the molecules that were affected by storage in PFA
in our study, only CD103 had decreased fluorescent inten-
sity. The other markers that were affected, TLR4, gamma-
delta T cell receptor, CCR7, BDCA-1, CX3CR1 and TLR2
actually had a slight increase in fluorescent intensity. In
more detailed analyses, we will need to take this change in
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be analyzed within 2 days.
An additional limitation of this study is the lack of a
live/dead exclusion gate. FSC and SSC gating was used
to eliminate cell debris, but cannot guarantee that all
dead cells were excluded. A final limitation is that the
protocol of the current SPIROMICS Immunophenotyp-
ing project does not include staining of intracellular
antigens, isolation of specific cell types or in vitro stimu-
lation to induce production of gene products such as cy-
tokines or inflammatory mediators. We considered those
undertakings premature until we had both demonstrated
the ability of this multi-center experimental design to
produce usable surface staining data, and had advanced
the characterization of specific cell types in our popula-
tion. However, given the technical success illustrated by
these results, we believe that such extension are entirely
feasible and should be an important goal of future stud-
ies in this cohort. For example, it would be of particular
interest to extend previous observations supporting a
role for granzyme B in the pathogenesis of emphysema
[46,47] by defining which cell types harvested by BAL
from area of radiographically-confirmed emphysema ex-
press that cytotoxic molecule.
Part of our future analysis strategy will be to correlate
the relative proportions of a given cell type in BAL ver-
sus sputum versus blood in the same subject. Other ana-
lyses will correlate cell-surface markers on a given cell
type with smoking history, spirometry, airway measure-
ments, and other parameters. As part of the parent
SPIROMICS project, individuals will also be character-
ized via physiological, imaging, biochemical, and genetic
parameters. These data will also be available for correlat-
ing with immunophenotyping analyses.Conclusion
In conclusion, we have demonstrated the feasibility of
providing state-of-the-art immunophenotyping of spu-
tum, peripheral blood and BAL in a multicenter obser-
vational study of COPD biomarkers. Key features of our
approach that minimize potential sources of experimen-
tal variation include “just-in-time” provision of reagents
from a centralized Immunophenotyping Core, local im-
munostaining and fixation, and return of samples for
analysis on a single flow cytometer. The choice of
leukocyte cell types and their receptors was based on a
series of pre-specified hypotheses plus research interests
of the coauthors. This interim report demonstrates the
success of our approach, which may be of value in the
design of multicenter trials in other disease states. Enroll-
ment to this sub-study is anticipated to be completed in
the summer of 2015, so results should be analyzed and
published over the next two years.Consent
Written informed consent was obtained from each
participant for the publication of this report and any
accompanying images.
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